T cells expressing an anti–B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma

Syed Abbas Ali, Victoria Shi, Irina Marić, +11

Blood

Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels

James N. Kochenderfer, Robert Somerville, Tangying Lu, +19

Journal of Clinical Oncology

Characterization of a New Humanized Anti-CD20 Monoclonal Antibody, IMMU-106, and Its Use in Combination with the Humanized Anti-CD22 Antibody, Epratuzumab, for the Therapy of Non-Hodgkin’s Lymphoma

Rhona Stein, Zhengxing Qu, Susan Chen, +6

Clinical Cancer Research

Combination anti-HIV antibodies provide sustained virological suppression

Michael C. Sneller, Jana Blažková, J. Shawn Justement, +17

Nature

Human RetrovirusImmunologyAntiviral ResponseVirologyChronic Viral Infection +4

A Longitudinal Study of COVID-19 Sequelae and Immunity: Baseline Findings

Michael C. Sneller, Chen Liang, Adriana Marques, +24

Annals of Internal Medicine

A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection

Michael C. Sneller, J. Shawn Justement, Kathleen Gittens, +18

Science Translational Medicine

Effect of analytical treatment interruption and reinitiation of antiretroviral therapy on HIV reservoirs and immunologic parameters in infected individuals

Katherine E. Clarridge, Jana Blažková, Kevin Einkauf, +12

PLoS Pathogens

ImmunologyHiv RemissionAntiviral DrugImmune SystemImmunotherapy +14

Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action

Zhengxing Qu, David M. Goldenberg, Thomas M. Cardillo, +3

Blood

Distinct mechanisms of long-term virologic control in two HIV-infected individuals after treatment interruption of anti-retroviral therapy

Jana Blažková, Feng Gao, Manukumar Honnayakanahalli Marichannegowda, +14

Nature Medicine

Distinct MechanismsHiv-infected IndividualsHuman RetrovirusImmunologyAntiviral Response +8

An open-label phase 1 clinical trial of the anti-α ₄ β ₇ monoclonal antibody vedolizumab in HIV-infected individuals

Michael C. Sneller, Katherine E. Clarridge, Catherine Seamon, +12

Science Translational Medicine